US WorldMeds' Opioid Withdrawal Drug Lofexidine Heads To US FDA Panel

Sponsor seeks a novel claim for facilitating completion of opioid discontinuation treatment, but agency's external experts will weigh in on evidentiary threshold for such an indication; FDA staff give mixed review to patient-reported outcomes instrument used as primary endpoint in two pivotal trials.